DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Melcher CA, Janni W, Rack B et al.
DETECT III – a multicenter, randomized, phase III study to compare standard therapy alone versus standard therapy plus lapatinib in patients with initially HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells.
Eur J Cancer 2012;
48: S95-S96
We do not assume any responsibility for the contents of the web pages of other providers.